Physician profile
Amy Flaherty
NPI 1508297524
$434.97
in general payments reported to CMS, 2019-2025
12 companies · $33.59 in 2025
The $33.59 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $95.28 · 2022: $74.27 · 2023: $201 · 2024: $30.34 · 2025: $33.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $265.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $99.15 | 2023-2024 | Orladeyo |
| Sanofi Pasteur INC. | $53.87 | 2022-2023 | |
| Pfizer INC. | $43.09 | 2022-2023 | |
| Neos Therapeutics, LP | $40.02 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.45 | 2021 | |
| Glaxosmithkline, LLC. | $35.97 | 2021-2023 | Bexsero |
| Sanofi-Aventis U.S. LLC | $33.59 | 2025 | |
| Kaleo, INC. | $27.60 | 2021 | |
| Seqirus USA INC | $17.91 | 2023 | Flucelvax Quadrivalent |
| Verrica Pharmaceuticals INC. | $16.13 | 2023 | Ycanth |
| Cranial Technologies, INC | $15.33 | 2022 | |
| Aytu Biopharma, INC. | $14.86 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Flaherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.